Omkar Pharmachem Ltd
- Market Cap ₹ 19.2 Cr.
- Current Price ₹ 19.0
- High / Low ₹ 29.7 / 17.3
- Stock P/E 160
- Book Value ₹ 36.3
- Dividend Yield 0.00 %
- ROCE 0.74 %
- ROE 0.52 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Stock is trading at 0.52 times its book value
- Debtor days have improved from 41.6 to 23.3 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 11.7% over past five years.
- Promoter holding is low: 0.03%
- Company has a low return on equity of 1.23% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.27 | 0.54 | 0.54 | 0.54 | 0.54 | 0.47 | |
| 0.06 | 0.12 | 0.22 | 0.24 | 0.38 | 0.26 | 0.24 | 0.27 | 0.22 | 0.25 | 0.24 | 0.31 | |
| Operating Profit | -0.06 | -0.12 | -0.22 | -0.24 | -0.38 | -0.21 | 0.03 | 0.27 | 0.32 | 0.29 | 0.30 | 0.16 |
| OPM % | -420.00% | 11.11% | 50.00% | 59.26% | 53.70% | 55.56% | 34.04% | |||||
| 0.00 | 0.00 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.05 | 0.06 | 0.06 | 0.05 | 0.03 | 0.02 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Profit before tax | -0.06 | -0.12 | 0.27 | -0.25 | -0.42 | -0.26 | -0.03 | 0.21 | 0.27 | 0.26 | 0.27 | 0.17 |
| Tax % | 0.00% | 0.00% | 18.52% | 0.00% | 0.00% | 0.00% | -866.67% | 14.29% | 25.93% | 23.08% | 25.93% | 23.53% |
| -0.06 | -0.12 | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.20 | 0.19 | 0.20 | 0.12 | |
| EPS in Rs | -0.06 | -0.12 | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.20 | 0.19 | 0.20 | 0.12 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | -5% |
| TTM: | -13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -11% |
| 3 Years: | -16% |
| TTM: | -40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -9% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 |
| Reserves | -0.81 | -0.93 | -0.71 | -0.96 | -1.38 | -1.64 | -1.42 | -1.24 | -1.04 | -0.85 | -0.65 | 26.56 |
| 0.01 | 0.00 | 0.00 | 0.24 | 0.58 | 0.87 | 0.90 | 0.93 | 0.62 | 0.30 | 0.12 | 0.00 | |
| 0.13 | 0.57 | 0.06 | 0.04 | 0.05 | 0.06 | 0.08 | 0.06 | 0.07 | 0.07 | 0.05 | 0.05 | |
| Total Liabilities | 9.41 | 9.72 | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 36.69 |
| 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 36.38 |
| 0.10 | 0.41 | 0.13 | 0.09 | 0.03 | 0.07 | 0.34 | 0.52 | 0.43 | 0.29 | 0.29 | 0.31 | |
| Total Assets | 9.41 | 9.72 | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 36.69 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.05 | 0.34 | -0.77 | -0.25 | -0.30 | -0.21 | 0.02 | 0.20 | 0.28 | 0.30 | 0.24 | 0.23 | |
| 0.00 | 0.00 | 0.49 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | |
| 0.00 | -0.01 | 0.01 | 0.23 | 0.30 | 0.24 | -0.02 | -0.03 | -0.35 | -0.35 | -0.20 | -0.12 | |
| Net Cash Flow | -0.05 | 0.33 | -0.28 | -0.03 | 0.00 | 0.02 | 0.00 | 0.17 | -0.08 | -0.06 | 0.04 | 0.11 |
| Free Cash Flow | -0.05 | 0.34 | -0.29 | -0.26 | -0.30 | -0.21 | 0.02 | 0.19 | 0.28 | 0.29 | 0.24 | 0.23 |
| CFO/OP | 83% | -283% | 327% | 104% | 79% | 100% | 67% | 74% | 88% | 103% | 80% | 138% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | 23.30 | |||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | 23.30 | |||||
| Working Capital Days | -6,570.00 | -1,270.74 | -608.33 | -378.52 | -162.22 | -6.76 | 23.30 | |||||
| ROCE % | -0.64% | -1.30% | -2.27% | -2.56% | -4.08% | -2.26% | 0.32% | 2.79% | 3.29% | 3.02% | 3.04% | 0.74% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Operating Segments Number |
|
|||||||||||
| Number of Permanent Employees Number |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
1 Jun - Dear Sir, Please find attached copy of News Paper Publication in which Audited Financial Results for the Quarter and Year ended 31st March 2026 are …
-
Financial Results For The Quarter And Year Ended 31.03.2026
30 May - Board approved audited FY2026 results on 30 May 2026; auditor issued unmodified opinion.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 30 May, 2026
30 May - Board approved audited FY2026 results on 30 May 2026; auditor issued unmodified opinion.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Omkar Pharmachem filed its Annual Secretarial Compliance Report for FY2025-26; no major non-compliances noted.
-
Board Meeting Intimation for Approval Of Audited Financial Results For Quarter And Year Ended On 31St March 2026
21 May - Board meeting on 30 May 2026 to approve audited March 31, 2026 financial results; trading window remains closed till June 1.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
OPL is in the business of pharmaceuticals,
chemicals, including Specialty chemicals,
Ciba Specialty Chemicals, Organic chemicals, etc., and to provide management and business support services. Currently, the company is only
engaged in the business of providing support services related to activities.